Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aptose Biosciences

1.71
+0.0000
Volume:- -
Turnover:- -
Market Cap:4.36M
PE:-0.05
High:1.71
Open:1.71
Low:1.71
Close:1.71
Loading ...

Aptose’s Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial

GlobeNewswire
·
12 Feb

Aptose Biosciences Price Target Maintained With a $2.00/Share by HC Wainwright & Co.

Dow Jones
·
10 Jan

Aptose Biosciences: Positive Outlook and Buy Rating Backed by Promising Tuspetinib Developments in AML Treatment

TIPRANKS
·
10 Jan

Aptose Biosciences Initiates TUSCANY Trial for Frontline AML Therapy

TIPRANKS
·
10 Jan

Aptose Biosciences Initiates Dosing in Early Study of Acute Myeloid Leukemia Treatment

MT Newswires Live
·
10 Jan

Aptose announces first AML patients dosed in TUSCANY trial

TIPRANKS
·
10 Jan

Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial

GlobeNewswire
·
10 Jan

Why Rumble Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket

Benzinga
·
23 Dec 2024

Top Midday Gainers

MT Newswires Live
·
21 Dec 2024

Aptose Biosciences Shares Almost Double Premarket After Nasdaq Grants Extension to be Compliant With Listing Rules

MT Newswires Live
·
20 Dec 2024

Aptose Biosciences Granted Nasdaq Compliance Extension

TIPRANKS
·
20 Dec 2024

Aptose Biosciences granted extension to regain compliance with Nasdaq

TIPRANKS
·
20 Dec 2024

Aptose Announces Positive Decision by Nasdaq Hearings Panel

GlobeNewswire
·
20 Dec 2024

Aptose Says Tusepetinib Preclinical Data Published in AACR Journal

MT Newswires
·
13 Dec 2024

Aptose Biosciences Publishes Promising Preclinical Data on Tuspetinib

TIPRANKS
·
12 Dec 2024

Aptose Biosciences announces publication of preclinical data on tuspetinib

TIPRANKS
·
12 Dec 2024

Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax

GlobeNewswire
·
12 Dec 2024

Aptose Biosciences Price Target Maintained With a $2.00/Share by HC Wainwright & Co.

Dow Jones
·
10 Dec 2024

Aptose Biosciences Advances TUS as AML Therapy

TIPRANKS
·
10 Dec 2024

Aptose Biosciences announces clinical data on tuspetinib

TIPRANKS
·
10 Dec 2024